Table 1 Clinical characteristics of the study’s patients (n = 412).
WFA+-M2BP ≤ 1.12 n = 175 (%) | WFA+-M2BP > 1.12 n = 237 (%) | p value | Total number of patients n = 412 (%) | ||
|---|---|---|---|---|---|
Age (years) | 60.17 ± 11.58 | 65.18 ± 9.87 | <0.001 | 63.05 ± 10.90 | |
Gender | Male | 146 (83.4) | 162 (68.4) | <0.001 | 308 (74.8) |
Female | 29 (16.6) | 75 (31.96) | 104 (25.2) | ||
BMI (kg/m2) | 24.31 ± 3.93 | 24.64 ± 3.50 | 0.373 | 24.50 ± 3.68 | |
Underlying disease | |||||
HBV | 125 (71.4) | 115 (48.5) | <0.001 | 240 (58.3) | |
HCV | 50 (28.6) | 122 (51.5) | 172 (41.7) | ||
Stage | |||||
I | 80 (45.7) | 81 (34.2) | 0.018 | 161 (39.1) | |
II | 95 (54.3) | 156 (65.8) | 251 (60.9) | ||
METAVIR Score | 0 | 2 (1.1) | 3 (1.3) | <0.001 | 5 (1.2) |
1 | 34 (19.4) | 16 (6.8) | 50 (12.1) | ||
2 | 64 (36.6) | 52 (21.9) | 116 (28.2) | ||
3 | 38 (21.7) | 56 (23.6) | 94 (22.8) | ||
4 | 37 (21.1) | 110 (46.4) | 147 (35.7) | ||
Fatty liver | 0.112 | ||||
Mild (0-1) | 155 (88.6) | 223 (94.1) | 378 (91.7) | ||
Moderate (2) | 16 (9.1) | 10 (4.2) | 26 (6.3) | ||
Severe (3) | 4 (2.3) | 4 (1.7) | 8 (1.9) | ||
AST (U/L) | 45.02 ± 49.72 | 63.91 ± 40.16 | <0.001 | 55.89 ± 45.39 | |
ALT (U/L) | 44.81 ± 50.04 | 60.04 ± 42.76 | 0.001 | 53.57 ± 46.55 | |
Alpha-fetoprotein (ng/mL) | 0.036 | ||||
20 ≤ | 111 (64.2) | 120 (51.7) | 231 (57.9) | ||
20–400 | 38 (22.0) | 74 (31.9) | 112 (27.7) | ||
>400 | 24 (13.9) | 38 (16.4) | 62 (15.3) | ||
Bilirubin (mg/dL) | 0.92 ± 1.50 | 0.87 ± 0.40 | 0.612 | 0.89 ± 1.02 | |
PLT (×103/µL) | 176.43 ± 55.40 | 152.57 ± 66.50 | 0.001 | 162.70 ± 63.07 | |
APTT (sec.) | 32.41 ± 4.70 | 32.38 ± 4.36 | 0.959 | 32.39 ± 4.50 | |
PT (sec.) | 11.40 ± 1.16 | 11.47 ± 1.28 | 0.527 | 11.44 ± 1.23 | |
INR | 1.06 ± 0.11 | 1.15 ± 0.86 | 0.166 | 1.11 ± 0.66 | |
Activity | 0 | 67 (38.3) | 64 (27.0) | 0.015 | 131 (31.8) |
1 | 108 (61.7) | 173 (73.0) | 281 (68.2) | ||
WFA+-M2BP | 0.76 ± 0.23 | 2.85 ± 2.23 | <0.001 | 1.96 ± 1.99 | |
Follow-up time | Median (SD) | 4.64 (2.09) | 4.15 (2.27) | 0.041 | 4.33 (2.21) |
